<DOC>
	<DOCNO>NCT00975975</DOCNO>
	<brief_summary>The purpose study compare effect ( good bad ) medication basiliximab combination cyclosporine ( investigational therapy ) prevention complication bone marrow transplantation know graft-versus-host disease ( GVHD ) . GVHD complication cell transplant bone marrow react organ tissue .</brief_summary>
	<brief_title>Basiliximab # 2 : In-Vivo Activated T-Cell Depletion Prevent Graft-Versus_Host Disease ( GVHD ) After Nonmyeloablative Allotransplantation Treatment Blood Cancer</brief_title>
	<detailed_description>This study patient blood condition myelodysplasia ( bone marrow disease ) either respond treatment treatable conventional/routine medical treatment . Bone marrow transplantation medical treatment involve give high dos chemotherapy follow transplantation blood-forming immune cell relative `` match '' unrelated person National Marrow Donor Program , attempt cure disease recipient ( person receive donated cell ) . Nonmyeloablative ( bone-marrow preservation ) bone marrow transplantation relatively new technique lower usual dos chemotherapy give transplantation , hop reduce adverse side effect chemotherapy transplant patient . Nonmyeloablative bone marrow transplantation several advantage doctor determine beneficial condition . This research do complication graft-versus-host disease bad person completely safe effective way prevent complication . We know cyclosporine help would like know addition basiliximab , give cyclosporine , decrease incidence and/or severity graft-versus-host disease transplant know nonmyeloablative `` mini '' transplant .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Primary Myelofibrosis</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Hemoglobinuria</mesh_term>
	<mesh_term>Hematologic Neoplasms</mesh_term>
	<mesh_term>Anemia , Aplastic</mesh_term>
	<mesh_term>Hemoglobinuria , Paroxysmal</mesh_term>
	<mesh_term>Basiliximab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Acute myelogenous leukemia : Second subsequent remission ; patient 18 yrs age . Relapsed autologous HC transplant , 18 year age . First remission , Philadelphia chromosome + age 18 . Secondary AML , first subsequent remission . Acute lymphocytic leukemia : Philadelphia chromosome + age 50 , first subsequent remission . Relapse follow Autologous HC transplantation , age 50 . Second subsequent remission age 50 Chronic myelogenous leukemia : First second chronic phase age 18 . Accelerated phase age 18 . Must fail intolerant standard tyrosine kinase inhibitor . Chronic lymphocytic leukemia : Failed nucleosidebased therapy , age &gt; 18 . Myelodysplasia : Allrisk category , age great 18 . NonHodgkin 's Lymphoma , less 76 year age Relapsed diffuse aggressive NHL ( intermediate high grade ) fail achieve CR PR conventional salvage chemotherapy . Aggressive NHL include diffuse large B cell lymphoma , diffuse mixed small large cell lymphoma , follicular lymphoma grade 3 ( follicular large cell lymphoma ) , T B cell lymphoblastic lymphoma , diffuse small noncleaved ( Burkett 's Burkettlike ) lymphoma , mantle cell lymphoma , peripheral T cell lymphoma , anaplastic large cell lymphoma , diffuse aggressive lymphoma otherwise classifiable Aggressive NHL relapse follow autologous HCT . Patients respond additional treatment posttransplant relapse eligible . Aggressive NHL achieve CR PR primary chemotherapy ( i.e. , primary induction failure ) . Lowgrade lymphoma refractory standard therapy , include follow : 1. small cell lymphocytic lymphoma , 2. follicular lymphoma grade 1 2 ( follicular small cleave follicular mixed small large cell lymphoma ) 3. marginal cell lymphoma , splenic lymphoma ) , 4. lymphoplasmacytic lymphoma 5. lymphomas otherwise classifiable . Patients lowgrade lymphoma must experience progressive disease receive three follow regimen : alkylatorbased therapy ( cyclophosphamide/ vincristine/ prednisone ) chlorambucil , monoclonal antibody base therapy ( e.g. , rituximab , Campath1H , radiolabelled CD20+ antibody ) ; nucleoside analogbased therapy ( e.g. , fludarabine , cladribine ) . ) Patients marginal zone lymphoma gastric MALT type associate Helicobacter pylori infection must progress receive appropriate antibiotic therapy well three regimen describe Mantle cell , age 1875 . Hodgkin 's Disease , age 1875 . Relapsed refractory disease autologous transplant . Multiple Myeloma , age 1875 Recurrent disease two medical therapy Relapse follow autologous transplant Myelofibrosis , age great 18 year Severe aplastic anemia ( refractory immunosuppressive therapy ) ; age great 18 year Patients aplastic anemia must marrow cellularity â‰¤ 10 % plus 2 following : 1 . Absolute granulocyte count &lt; 500/mm3 2 . Corrected reticulocyte count &lt; 1 % 3 . Untransfused platelet count &lt; 20,000/mm3 least 2 occasion 4 . Hemoglobin &lt; 9 g/dL ( adult ) &lt; 8 g/dL ( child ) least 2 occasion Paroxysmal nocturnal hemoglobinuria ; age great 18 year . Renal function : creatinine great 2.5 Donor Requirement : Must fully HLAmatched ( 10 10 Antigen match ) relate unrelated donor , eighteen year age old , capable undergoing GCSF mobilization apheresis Active CNS disease ( presence leukemic blast CSF ) Pregnancy breastfeed . Inability give inform consent . AST , ALT , total bilirubin &gt; 3x upper limit normal . Creatinine &gt; 2 creatinine clearance &lt; 50mL/hr . If patient creatinine &gt; 2 creatinine clearance &lt; 50mL/hr due disease process patient exclude base . Fractional shorten echocardiogram within normal limit per institution LVEF &lt; 40 % . Pulmonary function : DLCO within institutional normal limit DLCO le 45 % normal predict , correct anemia Prior allogeneic transplant .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Paroxysmal nocturnal hemoglobinuria</keyword>
	<keyword>severe aplastic anemia</keyword>
	<keyword>Mantle cell</keyword>
</DOC>